Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors | Zendy

Yuki Takeyasu | Zendy; Hitomi Sumiyoshi Okuma | Zendy; Yuki Kojima | Zendy; Tadaaki Nishikawa | Zendy; Maki Tanioka | Zendy; Kazuki Sudo | Zendy; Tatsunori Shimoi | Zendy; Emi Noguchi | Zendy; Ayumu Arakawa | Zendy; Taisuke Mori | Zendy; Kuniko Sunami | Zendy; Takashi Kubo | Zendy; Takashi Kohno | Zendy; Yoshida Akihiko | Zendy; Noboru Yamamoto | Zendy; Kan Yonemori | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors

Author(s) -

Yuki Takeyasu,

Hitomi Sumiyoshi Okuma,

Yuki Kojima,

Tadaaki Nishikawa,

Maki Tanioka,

Kazuki Sudo,

Tatsunori Shimoi,

Emi Noguchi,

Ayumu Arakawa,

Taisuke Mori,

Kuniko Sunami,

Takashi Kubo,

Takashi Kohno,

Yoshida Akihiko,

Noboru Yamamoto,

Kan Yonemori

Publication year - 2021

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.20.00383

Subject(s) - crizotinib , alectinib , anaplastic lymphoma kinase , medicine , alk inhibitor , gene rearrangement , lung cancer , cancer research , targeted therapy , oncology , cancer , biology , malignant pleural effusion , biochemistry , gene

Anaplastic lymphoma kinase ( ALK ) rearrangement is a well-known driver oncogene in non-small-cell lung cancer and has also been identified in other types of tumors. However, there is limited evidence on the clinical response to ALK tyrosine kinase inhibitors (TKIs), such as alectinib and crizotinib, in rare tumors with ALK fusion. We evaluated the therapeutic effect of ALK-TKIs in rare ALK -rearranged tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research